COX-2s, NSAIDs and heart failure
This article was originally published in The Tan Sheet
Executive SummaryRate of hospital admission for congestive heart failure was "significantly higher" for users of non-selective NSAIDs and Merck's Vioxx (rofecoxib) but not for Pfizer's Celebrex (celecoxib), Muhammad Mamdani, Institute for Clinical Evaluative Sciences, Toronto, Ontario et al. find in a study published in the May 29 issue of The Lancet. Retrospective cohort study reviewed data on 1.3 mil. individuals ages 65 years or older who used either Vioxx, Celebrex or non-selective non-steroidal anti-inflammatory drugs for one year or who were non-NSAID users. The total number of admissions for congestive heart failure in the cohort was 654. The authors note they conducted the study because while COX-2 inhibitors previously have been associated with a lower risk of gastrointestinal events than non-selective NSAIDs, "the cardiovascular safety of [COX-2s] has been challenged"...
You may also be interested in...
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.